ArticleJCO precision oncology2026
Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlioblastoma (GBM) is an aggressive brain tumor characterized by extensive heterogeneity and inevitable recurrence. Although extracranial metastases are rare, circulating tumor cells (CTCs) are consistently detectable in patients with GBM, challenging the idea of GBM as a strictly localized disease and suggesting CTCs as a promising liquid biopsy tool.
methodsWe analyzed genomic and phenotypic features of bulk CTCs (BCTCs) and single CTCs in 27 patients with GBM. Whole-exome sequencing of BCTCs and matched tumors confirmed tumor origin and assessed shared mutational and copy number alteration (CNA) profiles. Single CTCs isolated with DEPArray NxT underwent low-pass whole-genome sequencing. CTCs counts were compared across primary GBM, recurrent GBM, healthy donors, and non-GBM conditions. Single-cell RNA-seq from primary GBM cell lines was used to validate observations.
resultsBCTCs showed genomic alterations overlapping with those of matched tumors. CTCs were significantly more abundant in primary GBM than in recurrent disease or healthy controls, enabling the definition of a diagnostic cutoff of 4 CTCs per 5 mL of blood. CTCs were absent in the small cohort of radionecrosis cases analyzed, suggesting a potential role for CTCs in distinguishing neoplastic from non-neoplastic lesions, although further validation in larger cohorts is required. Single-cell analysis revealed marked heterogeneity, including CTCs lacking detectable CNAs. Similar CNA-negative populations appeared in scRNA-seq data sets, suggesting possible origin from the tumor microenvironment rather than fully malignant clones.
conclusionCTCs are tumor-derived and heterogeneous biomarkers with strong diagnostic potential in GBM. The identified cutoff improves distinction between GBM and non-neoplastic diseases, supporting CTCs as a useful liquid biopsy tool for detection and monitoring. Further studies should clarify the biologic roles of distinct CTCs subpopulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.